Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
Compare the Accuracy of Circulating Tumor DNA Longitudinal Monitoring Minimal Residual Disease and Microvascular Invasion Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
Sponsor: Zhujiang Hospital
Listed as NCT06449846, this observational or N/A phase trial focuses on Hepatocellular Carcinoma Resectable and Recurrence and remains actively recruiting participants. Sponsored by Zhujiang Hospital, it has been updated 2 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
2 versions recorded-
Sep 2024 — Present [monthly]
Not Yet Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting
First recorded
Jun 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Zhujiang Hospital
For direct contact, visit the study record on ClinicalTrials.gov .